Recent experience with 89 pancreas transplants at a single institution.
Of 89 pancreas transplants performed in 77 diabetic patients (43 with and 34 without previous kidney transplants), 53 were from cadaver and 36 from related donors. To date, 64 patients (83%) are alive and 27 (35%) have functioning grafts (14 greater than 1 year), including 0 out of 3 duct-ligated, 3 out of 15 open-duct, 17 out of 32 enteric-drained, and 7 out of 39 duct-injected. Of technically successful allografts, 8 out of 16 (50%) in the azathioprine- and 17 out of 47 (36%) in the cyclosporin-treated recipients are functioning (eight cyclosporin patients also take azathioprine). Seven of the nine (78%) non-kidney-transplants recipients of technically successful pancreas allografts from HLA-identical siblings have functioning grafts. Causes of graft failure include allograft rejection, fibrosis secondary to duct injection, or selective beta-cell destruction independent of rejection. Of the 24 recipients who are currently insulin-dependent, 14 have normal or near-normal glucose tolerance test results, while 10 have abnormal results, even though they are otherwise euglycaemic. The patient population to whom pancreas transplantation is applied is gradually changing, and non-uraemic, non-kidney-transplant patients currently comprise the majority of our cases (17 out of 24 in 1983; nine of the 17 currently have functioning grafts). We now prefer the enteric drainage technique.(ABSTRACT TRUNCATED AT 250 WORDS)
D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D003524:Cyclosporins / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D008722:Methods; D008875:Middle Aged; D016035:Pancreas Transplantation; D014181:Transplantation Immunology
D001786:Blood Glucose; D003524:Cyclosporins; D001379:Azathioprine